News >

Ipilimumab Effective in Adolescents With Advanced Melanoma

Jason Harris
Published: Thursday, Nov 30, 2017

Ipilimumab (Yervoy) was associated with a 1-year overall survival (OS) rate of 75% in adolescent patients with stage III/IV unresectable malignant melanoma.

One patient in the 3 mg/kg cohort and 5 in the 10 mg/kg grout reported experiencing grade 3/4 immune-mediated adverse reactions. There were no treatment-related deaths recorded. However, half of the patients in the 3 mg/kg cohort and 3 (38%) in the 10 mg/kg cohort died from disease progression at the time of study closure.
Geoerger B, Bergeron C, Gore L, et al. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. Eur J Cancer. 2017;86:358-363. doi:10.1016/j.ejca.2017.09.032.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x